CLL Society Honors Researchers for Advancements in Leukemia and Lymphoma Care

The CLL Society's 2025 Research Program awards have spotlighted three researchers whose work promises to enhance the care and treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). These awards, including the Integrative Medicine Award, Clinical Scholar Award, and Young Investigator Award, are pivotal in supporting research that bridges gaps in current treatment methodologies and patient care strategies.

Dr. Nancy Musoke's receipt of the Integrative Medicine Award highlights the importance of non-pharmacologic interventions in early-stage CLL/SLL. Her study on curcumin supplementation and physical activity's effects on disease progression and immune function opens new avenues for patient care beyond traditional medicine.

Dr. Matthew S. Davids, awarded the Clinical Scholar Award, is focusing on a less toxic and more effective treatment for Richter’s transformation, a dire complication of CLL. His research on optimizing glofitamab combination therapy could significantly alter the treatment landscape for this aggressive disease progression.

The Young Investigator Award was bestowed upon Dr. Quinlan Sievers for his exploration into resistance mechanisms to BTK inhibitors, a key treatment for CLL/SLL. His work is crucial for developing more durable and personalized therapies, especially for patients facing relapse.

These awards reflect the CLL Society's dedication to fostering research that addresses the most pressing challenges in CLL/SLL care. For further details on the groundbreaking research supported by the CLL Society, visit https://cllsociety.org/what-we-fund/.